Dendrimer conjugates
First Claim
1. A dendrimer conjugate comprising a linker,wherein said linker is selected from the group consisting of an elimination linker, a cyclization linker, a glucoronidase sensitive linker, a branched self-elimination linker, a heteroaromatic nitrogen containing compound linker, and a hypoxia induced linker,wherein said linker is conjugated toa) a G5 PAMAM dendrimer;
- b) a targeting agent; and
c) a therapeutic compound.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer-linker conjugates, methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer-linker conjugates of the present invention may further comprise one or more components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy.
111 Citations
7 Claims
-
1. A dendrimer conjugate comprising a linker,
wherein said linker is selected from the group consisting of an elimination linker, a cyclization linker, a glucoronidase sensitive linker, a branched self-elimination linker, a heteroaromatic nitrogen containing compound linker, and a hypoxia induced linker, wherein said linker is conjugated to a) a G5 PAMAM dendrimer; -
b) a targeting agent; and c) a therapeutic compound. - View Dependent Claims (2, 3, 4, 5, 6, 7)
-
Specification